#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=The impact of psychosis genome-wide associated ZNF804A variation on verbal fluency connectivity Schizophrenia (SCZ) and bipolar disorder (BD) have high heritability.
1-1	0-3	The	_
1-2	4-10	impact	_
1-3	11-13	of	_
1-4	14-23	psychosis	_
1-5	24-35	genome-wide	_
1-6	36-46	associated	_
1-7	47-54	ZNF804A	_
1-8	55-64	variation	_
1-9	65-67	on	_
1-10	68-74	verbal	_
1-11	75-82	fluency	_
1-12	83-95	connectivity	_
1-13	96-109	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-14	110-111	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	112-115	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	116-117	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	118-121	and	_
1-18	122-129	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-19	130-138	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-20	139-140	(	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-21	141-143	BD	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-22	144-145	)	_
1-23	146-150	have	_
1-24	151-155	high	_
1-25	156-168	heritability	_
1-26	169-170	.	_

Text=Genome-wide association studies (GWAS) have identified ZNF804A as a significant risk gene for both illnesses.
2-1	171-182	Genome-wide	_
2-2	183-194	association	_
2-3	195-202	studies	_
2-4	203-204	(	_
2-5	205-209	GWAS	_
2-6	210-211	)	_
2-7	212-216	have	_
2-8	217-227	identified	_
2-9	228-235	ZNF804A	_
2-10	236-238	as	_
2-11	239-240	a	_
2-12	241-252	significant	_
2-13	253-257	risk	_
2-14	258-262	gene	_
2-15	263-266	for	_
2-16	267-271	both	_
2-17	272-281	illnesses	_
2-18	282-283	.	_

Text=A validation of this finding at the brain systems-level is imperative as there is still little understanding of how it heightens risk.
3-1	284-285	A	_
3-2	286-296	validation	_
3-3	297-299	of	_
3-4	300-304	this	_
3-5	305-312	finding	_
3-6	313-315	at	_
3-7	316-319	the	_
3-8	320-325	brain	_
3-9	326-339	systems-level	_
3-10	340-342	is	_
3-11	343-353	imperative	_
3-12	354-356	as	_
3-13	357-362	there	_
3-14	363-365	is	_
3-15	366-371	still	_
3-16	372-378	little	_
3-17	379-392	understanding	_
3-18	393-395	of	_
3-19	396-399	how	_
3-20	400-402	it	_
3-21	403-412	heightens	_
3-22	413-417	risk	_
3-23	418-419	.	_

Text=Based in part on our recent findings of an effect on widespread decreased white matter microstructural fractional anisotropy (putatively a proxy of its integrity), particularly strong in SCZ, we asked whether the risk allele has a detrimental effect on regional brain activation and functional connectivity during a type of cognitive processing which is, together with its neural correlates, impaired in BD and SCZ: verbal fluency.
4-1	420-425	Based	_
4-2	426-428	in	_
4-3	429-433	part	_
4-4	434-436	on	_
4-5	437-440	our	_
4-6	441-447	recent	_
4-7	448-456	findings	_
4-8	457-459	of	_
4-9	460-462	an	_
4-10	463-469	effect	_
4-11	470-472	on	_
4-12	473-483	widespread	_
4-13	484-493	decreased	_
4-14	494-499	white	_
4-15	500-506	matter	_
4-16	507-522	microstructural	_
4-17	523-533	fractional	_
4-18	534-544	anisotropy	_
4-19	545-546	(	_
4-20	547-557	putatively	_
4-21	558-559	a	_
4-22	560-565	proxy	_
4-23	566-568	of	_
4-24	569-572	its	_
4-25	573-582	integrity	_
4-26	583-584	)	_
4-27	585-586	,	_
4-28	587-599	particularly	_
4-29	600-606	strong	_
4-30	607-609	in	_
4-31	610-613	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-32	614-615	,	_
4-33	616-618	we	_
4-34	619-624	asked	_
4-35	625-632	whether	_
4-36	633-636	the	_
4-37	637-641	risk	_
4-38	642-648	allele	_
4-39	649-652	has	_
4-40	653-654	a	_
4-41	655-666	detrimental	_
4-42	667-673	effect	_
4-43	674-676	on	_
4-44	677-685	regional	_
4-45	686-691	brain	_
4-46	692-702	activation	_
4-47	703-706	and	_
4-48	707-717	functional	_
4-49	718-730	connectivity	_
4-50	731-737	during	_
4-51	738-739	a	_
4-52	740-744	type	_
4-53	745-747	of	_
4-54	748-757	cognitive	_
4-55	758-768	processing	_
4-56	769-774	which	_
4-57	775-777	is	_
4-58	778-779	,	_
4-59	780-788	together	_
4-60	789-793	with	_
4-61	794-797	its	_
4-62	798-804	neural	_
4-63	805-815	correlates	_
4-64	816-817	,	_
4-65	818-826	impaired	_
4-66	827-829	in	_
4-67	830-832	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-68	833-836	and	_
4-69	837-840	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-70	841-842	:	_
4-71	843-849	verbal	_
4-72	850-857	fluency	_
4-73	858-859	.	_

Text=Functional MRI and genotype data was collected from 80 healthy volunteers, and 54 SCZ and 40 BD patients.
5-1	860-870	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-2	871-874	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-3	875-878	and	_
5-4	879-887	genotype	_
5-5	888-892	data	_
5-6	893-896	was	_
5-7	897-906	collected	_
5-8	907-911	from	_
5-9	912-914	80	_
5-10	915-922	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-11	923-933	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-12	934-935	,	_
5-13	936-939	and	_
5-14	940-942	54	_
5-15	943-946	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-16	947-950	and	_
5-17	951-953	40	_
5-18	954-956	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-19	957-965	patients	_
5-20	966-967	.	_

Text=A standard multifactorial analysis of variance using statistical parametric mapping and significance correction of FWE p <0.05 was used.
6-1	968-969	A	_
6-2	970-978	standard	_
6-3	979-993	multifactorial	_
6-4	994-1002	analysis	_
6-5	1003-1005	of	_
6-6	1006-1014	variance	_
6-7	1015-1020	using	_
6-8	1021-1032	statistical	_
6-9	1033-1043	parametric	_
6-10	1044-1051	mapping	_
6-11	1052-1055	and	_
6-12	1056-1068	significance	_
6-13	1069-1079	correction	_
6-14	1080-1082	of	_
6-15	1083-1086	FWE	_
6-16	1087-1088	p	_
6-17	1089-1090	<	_
6-18	1091-1095	0.05	_
6-19	1096-1099	was	_
6-20	1100-1104	used	_
6-21	1105-1106	.	_

Text=We found the GWAS risk allele A was associated with decreased positive functional coupling between the left precentral gyrus/inferior frontal gyrus (i.e.
7-1	1107-1109	We	_
7-2	1110-1115	found	_
7-3	1116-1119	the	_
7-4	1120-1124	GWAS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-5	1125-1129	risk	_
7-6	1130-1136	allele	_
7-7	1137-1138	A	_
7-8	1139-1142	was	_
7-9	1143-1153	associated	_
7-10	1154-1158	with	_
7-11	1159-1168	decreased	_
7-12	1169-1177	positive	_
7-13	1178-1188	functional	_
7-14	1189-1197	coupling	_
7-15	1198-1205	between	_
7-16	1206-1209	the	_
7-17	1210-1214	left	_
7-18	1215-1225	precentral	_
7-19	1226-1240	gyrus/inferior	_
7-20	1241-1248	frontal	_
7-21	1249-1254	gyrus	_
7-22	1255-1256	(	_
7-23	1257-1260	i.e	_
7-24	1261-1262	.	_

Text=the most highly recruited area for the task) and: 1) the left inferior frontal gyrus, and 2) the left posterior cingulate gyrus, encompassing the precuneus; both as a main effect across controls and psychosis patients.
8-1	1263-1266	the	_
8-2	1267-1271	most	_
8-3	1272-1278	highly	_
8-4	1279-1288	recruited	_
8-5	1289-1293	area	_
8-6	1294-1297	for	_
8-7	1298-1301	the	_
8-8	1302-1306	task	_
8-9	1307-1308	)	_
8-10	1309-1312	and	_
8-11	1313-1314	:	_
8-12	1315-1316	1	_
8-13	1317-1318	)	_
8-14	1319-1322	the	_
8-15	1323-1327	left	_
8-16	1328-1336	inferior	_
8-17	1337-1344	frontal	_
8-18	1345-1350	gyrus	_
8-19	1351-1352	,	_
8-20	1353-1356	and	_
8-21	1357-1358	2	_
8-22	1359-1360	)	_
8-23	1361-1364	the	_
8-24	1365-1369	left	_
8-25	1370-1379	posterior	_
8-26	1380-1389	cingulate	_
8-27	1390-1395	gyrus	_
8-28	1396-1397	,	_
8-29	1398-1410	encompassing	_
8-30	1411-1414	the	_
8-31	1415-1424	precuneus	_
8-32	1425-1426	;	_
8-33	1427-1431	both	_
8-34	1432-1434	as	_
8-35	1435-1436	a	_
8-36	1437-1441	main	_
8-37	1442-1448	effect	_
8-38	1449-1455	across	_
8-39	1456-1464	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-40	1465-1468	and	_
8-41	1469-1478	psychosis	_
8-42	1479-1487	patients	_
8-43	1488-1489	.	_

Text=Such association of the risk allele with reduced functional connectivity (with no area where the opposite main effect was detected), converges with findings in other tasks, our previous finding of its widespread impact on brain white matter microstructure, and with the dysconnectivity hypothesis of SCZ.
9-1	1490-1494	Such	_
9-2	1495-1506	association	_
9-3	1507-1509	of	_
9-4	1510-1513	the	_
9-5	1514-1518	risk	_
9-6	1519-1525	allele	_
9-7	1526-1530	with	_
9-8	1531-1538	reduced	_
9-9	1539-1549	functional	_
9-10	1550-1562	connectivity	_
9-11	1563-1564	(	_
9-12	1565-1569	with	_
9-13	1570-1572	no	_
9-14	1573-1577	area	_
9-15	1578-1583	where	_
9-16	1584-1587	the	_
9-17	1588-1596	opposite	_
9-18	1597-1601	main	_
9-19	1602-1608	effect	_
9-20	1609-1612	was	_
9-21	1613-1621	detected	_
9-22	1622-1623	)	_
9-23	1624-1625	,	_
9-24	1626-1635	converges	_
9-25	1636-1640	with	_
9-26	1641-1649	findings	_
9-27	1650-1652	in	_
9-28	1653-1658	other	_
9-29	1659-1664	tasks	_
9-30	1665-1666	,	_
9-31	1667-1670	our	_
9-32	1671-1679	previous	_
9-33	1680-1687	finding	_
9-34	1688-1690	of	_
9-35	1691-1694	its	_
9-36	1695-1705	widespread	_
9-37	1706-1712	impact	_
9-38	1713-1715	on	_
9-39	1716-1721	brain	_
9-40	1722-1727	white	_
9-41	1728-1734	matter	_
9-42	1735-1749	microstructure	_
9-43	1750-1751	,	_
9-44	1752-1755	and	_
9-45	1756-1760	with	_
9-46	1761-1764	the	_
9-47	1765-1780	dysconnectivity	_
9-48	1781-1791	hypothesis	_
9-49	1792-1794	of	_
9-50	1795-1798	SCZ	_
9-51	1799-1800	.	_

Text=Material and methods We genotyped (for ZNF804A rs1344706) and scanned, with functional MRI, 174 English native speakers [80 healthy volunteers without history of mental illness, 54 patients with SCZ and 40 with BD (75% of whom had a history of psychosis symptoms)], recruited from the SLAM NHS Trust and diagnosed according to DSM-IV (methodological detail and references are available in Supplement 1).
10-1	1801-1809	Material	_
10-2	1810-1813	and	_
10-3	1814-1821	methods	_
10-4	1822-1824	We	_
10-5	1825-1834	genotyped	_
10-6	1835-1836	(	_
10-7	1837-1840	for	_
10-8	1841-1848	ZNF804A	_
10-9	1849-1858	rs1344706	_
10-10	1859-1860	)	_
10-11	1861-1864	and	_
10-12	1865-1872	scanned	_
10-13	1873-1874	,	_
10-14	1875-1879	with	_
10-15	1880-1890	functional	_
10-16	1891-1894	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-17	1895-1896	,	_
10-18	1897-1900	174	_
10-19	1901-1908	English	_
10-20	1909-1915	native	_
10-21	1916-1924	speakers	_
10-22	1925-1926	[	_
10-23	1927-1929	80	_
10-24	1930-1937	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-25	1938-1948	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-26	1949-1956	without	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-27	1957-1964	history	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-28	1965-1967	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-29	1968-1974	mental	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-30	1975-1982	illness	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-31	1983-1984	,	_
10-32	1985-1987	54	_
10-33	1988-1996	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-34	1997-2001	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-35	2002-2005	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-36	2006-2009	and	_
10-37	2010-2012	40	_
10-38	2013-2017	with	_
10-39	2018-2020	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-40	2021-2022	(	_
10-41	2023-2025	75	_
10-42	2026-2027	%	_
10-43	2028-2030	of	_
10-44	2031-2035	whom	_
10-45	2036-2039	had	_
10-46	2040-2041	a	_
10-47	2042-2049	history	_
10-48	2050-2052	of	_
10-49	2053-2062	psychosis	_
10-50	2063-2071	symptoms	_
10-51	2072-2073	)	_
10-52	2074-2075	]	_
10-53	2076-2077	,	_
10-54	2078-2087	recruited	_
10-55	2088-2092	from	_
10-56	2093-2096	the	_
10-57	2097-2101	SLAM	_
10-58	2102-2105	NHS	_
10-59	2106-2111	Trust	_
10-60	2112-2115	and	_
10-61	2116-2125	diagnosed	_
10-62	2126-2135	according	_
10-63	2136-2138	to	_
10-64	2139-2145	DSM-IV	_
10-65	2146-2147	(	_
10-66	2148-2162	methodological	_
10-67	2163-2169	detail	_
10-68	2170-2173	and	_
10-69	2174-2184	references	_
10-70	2185-2188	are	_
10-71	2189-2198	available	_
10-72	2199-2201	in	_
10-73	2202-2212	Supplement	_
10-74	2213-2214	1	_
10-75	2215-2216	)	_
10-76	2217-2218	.	_

Text=This yielded 84 rs134470684 allele A homozygotes and 90 allele C carriers, and given the very low frequency of allele C in Caucasian population, we grouped the non-risk allele C homozygotes with the heterozygotes.
11-1	2219-2223	This	_
11-2	2224-2231	yielded	_
11-3	2232-2234	84	_
11-4	2235-2246	rs134470684	_
11-5	2247-2253	allele	_
11-6	2254-2255	A	_
11-7	2256-2267	homozygotes	_
11-8	2268-2271	and	_
11-9	2272-2274	90	_
11-10	2275-2281	allele	_
11-11	2282-2283	C	_
11-12	2284-2292	carriers	_
11-13	2293-2294	,	_
11-14	2295-2298	and	_
11-15	2299-2304	given	_
11-16	2305-2308	the	_
11-17	2309-2313	very	_
11-18	2314-2317	low	_
11-19	2318-2327	frequency	_
11-20	2328-2330	of	_
11-21	2331-2337	allele	_
11-22	2338-2339	C	_
11-23	2340-2342	in	_
11-24	2343-2352	Caucasian	_
11-25	2353-2363	population	_
11-26	2364-2365	,	_
11-27	2366-2368	we	_
11-28	2369-2376	grouped	_
11-29	2377-2380	the	_
11-30	2381-2389	non-risk	_
11-31	2390-2396	allele	_
11-32	2397-2398	C	_
11-33	2399-2410	homozygotes	_
11-34	2411-2415	with	_
11-35	2416-2419	the	_
11-36	2420-2433	heterozygotes	_
11-37	2434-2435	.	_

Text=The study was approved and reviewed by the National Health Service (NHS) South East London Research Ethics Committee, UK (Project “ Genetics and Psychosis (GAP) ” reference number 047/04) and was carried in accordance with the latest version of the Declaration of Helsinki.
12-1	2436-2439	The	_
12-2	2440-2445	study	_
12-3	2446-2449	was	_
12-4	2450-2458	approved	_
12-5	2459-2462	and	_
12-6	2463-2471	reviewed	_
12-7	2472-2474	by	_
12-8	2475-2478	the	_
12-9	2479-2487	National	_
12-10	2488-2494	Health	_
12-11	2495-2502	Service	_
12-12	2503-2504	(	_
12-13	2505-2508	NHS	_
12-14	2509-2510	)	_
12-15	2511-2516	South	_
12-16	2517-2521	East	_
12-17	2522-2528	London	_
12-18	2529-2537	Research	_
12-19	2538-2544	Ethics	_
12-20	2545-2554	Committee	_
12-21	2555-2556	,	_
12-22	2557-2559	UK	_
12-23	2560-2561	(	_
12-24	2562-2569	Project	_
12-25	2570-2571	“	_
12-26	2572-2580	Genetics	_
12-27	2581-2584	and	_
12-28	2585-2594	Psychosis	_
12-29	2595-2596	(	_
12-30	2597-2600	GAP	_
12-31	2601-2602	)	_
12-32	2603-2604	”	_
12-33	2605-2614	reference	_
12-34	2615-2621	number	_
12-35	2622-2628	047/04	_
12-36	2629-2630	)	_
12-37	2631-2634	and	_
12-38	2635-2638	was	_
12-39	2639-2646	carried	_
12-40	2647-2649	in	_
12-41	2650-2660	accordance	_
12-42	2661-2665	with	_
12-43	2666-2669	the	_
12-44	2670-2676	latest	_
12-45	2677-2684	version	_
12-46	2685-2687	of	_
12-47	2688-2691	the	_
12-48	2692-2703	Declaration	_
12-49	2704-2706	of	_
12-50	2707-2715	Helsinki	_
12-51	2716-2717	.	_

Text=Informed consent of the participants was obtained after the nature of the procedures had been fully explained.
13-1	2718-2726	Informed	_
13-2	2727-2734	consent	_
13-3	2735-2737	of	_
13-4	2738-2741	the	_
13-5	2742-2754	participants	_
13-6	2755-2758	was	_
13-7	2759-2767	obtained	_
13-8	2768-2773	after	_
13-9	2774-2777	the	_
13-10	2778-2784	nature	_
13-11	2785-2787	of	_
13-12	2788-2791	the	_
13-13	2792-2802	procedures	_
13-14	2803-2806	had	_
13-15	2807-2811	been	_
13-16	2812-2817	fully	_
13-17	2818-2827	explained	_
13-18	2828-2829	.	_

Text=There were no demographic differences (at p <0.05) between genotype or diagnostic groups, other than CPZ-equivalent medication and male: female being higher, and IQ lower, in patients with SCZ (see sample's demographics in Supplement 2).
14-1	2830-2835	There	_
14-2	2836-2840	were	_
14-3	2841-2843	no	_
14-4	2844-2855	demographic	_
14-5	2856-2867	differences	_
14-6	2868-2869	(	_
14-7	2870-2872	at	_
14-8	2873-2874	p	_
14-9	2875-2876	<	_
14-10	2877-2881	0.05	_
14-11	2882-2883	)	_
14-12	2884-2891	between	_
14-13	2892-2900	genotype	_
14-14	2901-2903	or	_
14-15	2904-2914	diagnostic	_
14-16	2915-2921	groups	_
14-17	2922-2923	,	_
14-18	2924-2929	other	_
14-19	2930-2934	than	_
14-20	2935-2949	CPZ-equivalent	_
14-21	2950-2960	medication	_
14-22	2961-2964	and	_
14-23	2965-2969	male	_
14-24	2970-2971	:	_
14-25	2972-2978	female	_
14-26	2979-2984	being	_
14-27	2985-2991	higher	_
14-28	2992-2993	,	_
14-29	2994-2997	and	_
14-30	2998-3000	IQ	_
14-31	3001-3006	lower	_
14-32	3007-3008	,	_
14-33	3009-3011	in	_
14-34	3012-3020	patients	_
14-35	3021-3025	with	_
14-36	3026-3029	SCZ	_
14-37	3030-3031	(	_
14-38	3032-3035	see	_
14-39	3036-3042	sample	_
14-40	3043-3045	's	_
14-41	3046-3058	demographics	_
14-42	3059-3061	in	_
14-43	3062-3072	Supplement	_
14-44	3073-3074	2	_
14-45	3075-3076	)	_
14-46	3077-3078	.	_

Text=The verbal fluency task [where subjects are required to overtly generate a word starting with a visually-displayed letter; or overtly read the word “ rest ” (control or repetition condition)], image acquisition, pre-processing and analysis using SPM software was performed as described earlier.
15-1	3079-3082	The	_
15-2	3083-3089	verbal	_
15-3	3090-3097	fluency	_
15-4	3098-3102	task	_
15-5	3103-3104	[	_
15-6	3105-3110	where	_
15-7	3111-3119	subjects	_
15-8	3120-3123	are	_
15-9	3124-3132	required	_
15-10	3133-3135	to	_
15-11	3136-3143	overtly	_
15-12	3144-3152	generate	_
15-13	3153-3154	a	_
15-14	3155-3159	word	_
15-15	3160-3168	starting	_
15-16	3169-3173	with	_
15-17	3174-3175	a	_
15-18	3176-3194	visually-displayed	_
15-19	3195-3201	letter	_
15-20	3202-3203	;	_
15-21	3204-3206	or	_
15-22	3207-3214	overtly	_
15-23	3215-3219	read	_
15-24	3220-3223	the	_
15-25	3224-3228	word	_
15-26	3229-3230	“	_
15-27	3231-3235	rest	_
15-28	3236-3237	”	_
15-29	3238-3239	(	_
15-30	3240-3247	control	_
15-31	3248-3250	or	_
15-32	3251-3261	repetition	_
15-33	3262-3271	condition	_
15-34	3272-3273	)	_
15-35	3274-3275	]	_
15-36	3276-3277	,	_
15-37	3278-3283	image	_
15-38	3284-3295	acquisition	_
15-39	3296-3297	,	_
15-40	3298-3312	pre-processing	_
15-41	3313-3316	and	_
15-42	3317-3325	analysis	_
15-43	3326-3331	using	_
15-44	3332-3335	SPM	_
15-45	3336-3344	software	_
15-46	3345-3348	was	_
15-47	3349-3358	performed	_
15-48	3359-3361	as	_
15-49	3362-3371	described	_
15-50	3372-3379	earlier	_
15-51	3380-3381	.	_

Text=A multifactorial ANOVA was used to test for the main effect of genotype (A homozygotes vs. C carriers) and its interaction with diagnosis (controls vs. BD vs. SCZ; or all psychosis patients, i.e.
16-1	3382-3383	A	_
16-2	3384-3398	multifactorial	_
16-3	3399-3404	ANOVA	_
16-4	3405-3408	was	_
16-5	3409-3413	used	_
16-6	3414-3416	to	_
16-7	3417-3421	test	_
16-8	3422-3425	for	_
16-9	3426-3429	the	_
16-10	3430-3434	main	_
16-11	3435-3441	effect	_
16-12	3442-3444	of	_
16-13	3445-3453	genotype	_
16-14	3454-3455	(	_
16-15	3456-3457	A	_
16-16	3458-3469	homozygotes	_
16-17	3470-3473	vs.	_
16-18	3474-3475	C	_
16-19	3476-3484	carriers	_
16-20	3485-3486	)	_
16-21	3487-3490	and	_
16-22	3491-3494	its	_
16-23	3495-3506	interaction	_
16-24	3507-3511	with	_
16-25	3512-3521	diagnosis	_
16-26	3522-3523	(	_
16-27	3524-3532	controls	_
16-28	3533-3536	vs.	_
16-29	3537-3539	BD	_
16-30	3540-3543	vs.	_
16-31	3544-3547	SCZ	_
16-32	3548-3549	;	_
16-33	3550-3552	or	_
16-34	3553-3556	all	_
16-35	3557-3566	psychosis	_
16-36	3567-3575	patients	_
16-37	3576-3577	,	_
16-38	3578-3581	i.e	_
16-39	3582-3583	.	_

Text=100% of SCZ group + 75% of BD group, vs. controls).
17-1	3584-3587	100	_
17-2	3588-3589	%	_
17-3	3590-3592	of	_
17-4	3593-3596	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-5	3597-3602	group	_
17-6	3603-3604	+	_
17-7	3605-3607	75	_
17-8	3608-3609	%	_
17-9	3610-3612	of	_
17-10	3613-3615	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
17-11	3616-3621	group	_
17-12	3622-3623	,	_
17-13	3624-3627	vs.	_
17-14	3628-3636	controls	_
17-15	3637-3638	)	_
17-16	3639-3640	.	_

Text=These effects were tested on whole-brain regional activation and on functional connectivity, including connectivity that would depend on task trials (i.e.
18-1	3641-3646	These	_
18-2	3647-3654	effects	_
18-3	3655-3659	were	_
18-4	3660-3666	tested	_
18-5	3667-3669	on	_
18-6	3670-3681	whole-brain	_
18-7	3682-3690	regional	_
18-8	3691-3701	activation	_
18-9	3702-3705	and	_
18-10	3706-3708	on	_
18-11	3709-3719	functional	_
18-12	3720-3732	connectivity	_
18-13	3733-3734	,	_
18-14	3735-3744	including	_
18-15	3745-3757	connectivity	_
18-16	3758-3762	that	_
18-17	3763-3768	would	_
18-18	3769-3775	depend	_
18-19	3776-3778	on	_
18-20	3779-3783	task	_
18-21	3784-3790	trials	_
18-22	3791-3792	(	_
18-23	3793-3796	i.e	_
18-24	3797-3798	.	_

Text=psychophysiological interaction; PPI).
19-1	3799-3818	psychophysiological	_
19-2	3819-3830	interaction	_
19-3	3831-3832	;	_
19-4	3833-3836	PPI	_
19-5	3837-3838	)	_
19-6	3839-3840	.	_

Text=Main effect of task is reported for completeness, but not discussed, as it has already been described in a highly overlapping sample.
20-1	3841-3845	Main	_
20-2	3846-3852	effect	_
20-3	3853-3855	of	_
20-4	3856-3860	task	_
20-5	3861-3863	is	_
20-6	3864-3872	reported	_
20-7	3873-3876	for	_
20-8	3877-3889	completeness	_
20-9	3890-3891	,	_
20-10	3892-3895	but	_
20-11	3896-3899	not	_
20-12	3900-3909	discussed	_
20-13	3910-3911	,	_
20-14	3912-3914	as	_
20-15	3915-3917	it	_
20-16	3918-3921	has	_
20-17	3922-3929	already	_
20-18	3930-3934	been	_
20-19	3935-3944	described	_
20-20	3945-3947	in	_
20-21	3948-3949	a	_
20-22	3950-3956	highly	_
20-23	3957-3968	overlapping	_
20-24	3969-3975	sample	_
20-25	3976-3977	.	_

Text=Incorrect response trials were excluded to avoid confounding effects of task performance.
21-1	3978-3987	Incorrect	_
21-2	3988-3996	response	_
21-3	3997-4003	trials	_
21-4	4004-4008	were	_
21-5	4009-4017	excluded	_
21-6	4018-4020	to	_
21-7	4021-4026	avoid	_
21-8	4027-4038	confounding	_
21-9	4039-4046	effects	_
21-10	4047-4049	of	_
21-11	4050-4054	task	_
21-12	4055-4066	performance	_
21-13	4067-4068	.	_

Text=For connectivity, we used, as seed, the 6-mm radius sphere where the main effect of task was the highest (i.e.
22-1	4069-4072	For	_
22-2	4073-4085	connectivity	_
22-3	4086-4087	,	_
22-4	4088-4090	we	_
22-5	4091-4095	used	_
22-6	4096-4097	,	_
22-7	4098-4100	as	_
22-8	4101-4105	seed	_
22-9	4106-4107	,	_
22-10	4108-4111	the	_
22-11	4112-4116	6-mm	_
22-12	4117-4123	radius	_
22-13	4124-4130	sphere	_
22-14	4131-4136	where	_
22-15	4137-4140	the	_
22-16	4141-4145	main	_
22-17	4146-4152	effect	_
22-18	4153-4155	of	_
22-19	4156-4160	task	_
22-20	4161-4164	was	_
22-21	4165-4168	the	_
22-22	4169-4176	highest	_
22-23	4177-4178	(	_
22-24	4179-4182	i.e	_
22-25	4183-4184	.	_

Text=left precentral gyrus/inferior frontal gyrus, pars opercularis: −44 4 34).
23-1	4185-4189	left	_
23-2	4190-4200	precentral	_
23-3	4201-4215	gyrus/inferior	_
23-4	4216-4223	frontal	_
23-5	4224-4229	gyrus	_
23-6	4230-4231	,	_
23-7	4232-4236	pars	_
23-8	4237-4248	opercularis	_
23-9	4249-4250	:	_
23-10	4251-4254	−44	_
23-11	4255-4256	4	_
23-12	4257-4259	34	_
23-13	4260-4261	)	_
23-14	4262-4263	.	_

Text=ηp2 measures of effect size were calculated in R to assess how much of the inter-individual (+error) variance in peak activation was explained by genotype.
24-1	4264-4267	ηp2	_
24-2	4268-4276	measures	_
24-3	4277-4279	of	_
24-4	4280-4286	effect	_
24-5	4287-4291	size	_
24-6	4292-4296	were	_
24-7	4297-4307	calculated	_
24-8	4308-4310	in	_
24-9	4311-4312	R	_
24-10	4313-4315	to	_
24-11	4316-4322	assess	_
24-12	4323-4326	how	_
24-13	4327-4331	much	_
24-14	4332-4334	of	_
24-15	4335-4338	the	_
24-16	4339-4355	inter-individual	_
24-17	4356-4357	(	_
24-18	4358-4364	+error	_
24-19	4365-4366	)	_
24-20	4367-4375	variance	_
24-21	4376-4378	in	_
24-22	4379-4383	peak	_
24-23	4384-4394	activation	_
24-24	4395-4398	was	_
24-25	4399-4408	explained	_
24-26	4409-4411	by	_
24-27	4412-4420	genotype	_
24-28	4421-4422	.	_

